This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

An MRI substudy of a donepezil clinical trial in mild cognitive impairment


Schuff, Norbert, Suhy, Joyce, Goldman, Robert, Xu, Yikang, Sun, Yijun, Truran-Sacrey, Diana, Murthy, Anita


Neurobiology Of Aging, Volume: 32, No.: 12, Pages.: 2318.e31-41

Year of Publication



A magnetic resonance imaging (MRI) study was conducted as part of an intervention study in subjects with amnestic mild cognitive impairment (aMCI) to assess donepezil’s treatment effect on brain atrophy. Adults with aMCI were randomly assigned to double-blind treatment with 10 mg/day donepezil hydrochloride or placebo for 48 weeks. Brain MRI scans were acquired at baseline and endpoint. The primary outcome measure was annualized percentage change (APC) in hippocampal volume; the main secondary outcome measure was APC in whole brain volumes. An analysis of variance (ANOVA) model including terms for treatment, site, and age was used to compare the treatment groups. APCs for hippocampal volumes were not significantly different between treatment groups. There were significant differences favoring the donepezil group for total (p = 0.001), ventricular region (p = 0.0002), and cortical region (p = 0.003) whole brain volumes. Although the primary MRI outcome measure was negative, the main secondary MRI outcome measure showed a positive result. These findings suggest a treatment effect of donepezil on brain atrophy in aMCI.; Copyright © 2011 Elsevier Inc. All rights reserved.

Bibtex Citation

@article{Schuff_2011, doi = {10.1016/j.neurobiolaging.2010.04.005}, url = {}, year = 2011, month = {dec}, publisher = {Elsevier {BV}}, volume = {32}, number = {12}, pages = {2318.e31--2318.e41}, author = {Norbert Schuff and Joyce Suhy and Robert Goldman and Yikang Xu and Yijun Sun and Diana Truran-Sacrey and Anita Murthy}, title = {An {MRI} substudy of a donepezil clinical trial in mild cognitive impairment}, journal = {Neurobiology of Aging} }


aged, aged, 80 and over, atrophy, brain, diagnosis, donezepil, double-blind method, drug effects, drug therapy, female, humans, indans, magnetic resonance imaging, male, methods, middle aged, mild cognitive impairment, pathology, pharmacology, piperidines, psychology, therapeutic use

Countries of Study


Types of Dementia

Mild Cognitive Impairment (MCI)

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Pharmaceutical Interventions

Pharmaceutical Interventions

Anti-Alzheimer medications, e.g.: donezepil, galantamine, rivastigmine, memantime